Aspire Biopharma Holdings annual gross margin
2025
Aspire Biopharma Holdings Gross Margin Growth & History (ASBP)
Aspire Biopharma Holdings's gross margin was −1.87% for fiscal 2025.
View full Aspire Biopharma Holdings company overviewAspire Biopharma Holdings annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −1.87% | — |
Aspire Biopharma Holdings quarterly gross margin
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −47.68% | — |
| Q1 2026 | 2026-03-31 | 20.28% | — |
| Q4 2025 | 2025-12-31 | −23.47% | — |
| Q3 2025 | 2025-09-30 | 45.54% | — |
Aspire Biopharma Holdings gross margin trends
The latest reported quarter, Q2 2026, shows −47.68%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aspire Biopharma Holdings source filings ↗